Table 5 Safety evaluation of rmhTNF combined with cisplatin versus cisplatin alone through thoracic perfusion for treating MPE
Study | Fever (N) | Chest pain (N) | Myelosuppression (N) | Digestive reaction (N) | Liver and kidney dysfunction (N) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | |
Do W 2005 [20] | 21/30 | 1/30 | 13/30 | 18/30 | 11/30 | 10/30 | 17/30 | 14/30 | 1/30 | 1/30 |
Yanhao W 2006 [13] | 3/28 | 4/28 | 4/28 | 2/28 | 0/28 | 2/28 | 0/28 | 16/28 | – | – |
Zhijun W [26] | 5/53 | 2/31 | 5/53 | 2/31 | 5/53 | 3/31 | 4/53 | 4/31 | 2/53 | 2/31 |
Shimeng F 2010 [22] | 13/43 | 3/30 | 8/43 | 18/30 | 2/43 | 5/30 | 3/43 | 15/30 | – | – |
Hua Z 2010 [9] | 20/34 | 0/24 | 22/34 | 20/24 | – | – | 15/34 | 14/24 | – | – |
Xiqiang W 2010 [24] | 5/23 | 0/31 | – | – | 8/23 | 9/31 | 16/23 | 21/31 | 2/23 | 2/31 |
Haiyan C 2015 [10] | 2/26 | 1/27 | 3/26 | 4/27 | 2/26 | 3/27 | 4/26 | 2/27 | – | – |
Jin L 2015 [12] | 14/26 | 3/29 | 6/26 | 6/29 | 1/26 | 1/29 | 4/26 | 4/29 | 2/26 | 1/29 |
Tao H 2016 [23] | 14/30 | 5/30 | 13/30 | 10/30 | – | – | 7/30 | 9/30 | – | – |
Chun W 2016 [19] | 4/32 | 0/32 | – | – | – | – | – | – | – | – |
Hua Z 2017 [21] | 14/21 | 0/18 | 12/21 | 13/18 | – | – | 12/21 | 11/18 | – | – |
P < 0.05 | P > 0.05 | P > 0.05 | P > 0.05 | P > 0.05 | ||||||